BACKGROUND: @entity1737 is a condition in which neuromuscular transmission is affected by antibodies against @entity3161 components ( @entity6107 , MG; and @entity27939 gravis, NMG) or by defects in genes for @entity3161 proteins ( @entity8491 , CMSs). Clinically, some individuals seem to benefit from treatment with @entity6358 , but its effects and adverse effects have not been systematically evaluated. OBJECTIVES: To assess the effects and adverse effects of @entity6358 in @entity1 with @entity792 , transient neonatal MG, and the @entity8491 . SEARCH METHODS: On 17 November 2014, we searched the Cochrane @entity4094 Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE. We also searched reference lists of articles, conference proceedings of relevant conferences, and prospective trial registers. In addition, we contacted manufacturers and researchers in the field. SELECTION CRITERIA: We considered randomised controlled trials (RCTs) and quasi-RCTs comparing @entity6358 as a single or add-on treatment with any other active treatment, placebo, or no treatment in adults or @entity1 with @entity792 , NMG, or CMSs. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study design and quality, and extracted data. We contacted study authors for additional information. We collected information on adverse effects from included articles, and contacted authors. MAIN RESULTS: We found no RCTs or quasi-RCTs, and therefore could not establish the effect of @entity6358 on MG, NMG and CMSs. We describe the results of 53 non-randomised studies narratively in the Discussion section, including observations of endurance, muscle strength and quality of life. Effects may differ depending on the type of @entity1737 . Thirty-seven studies were in @entity1 with CMS, five in @entity1 with MG, and in 11 the precise form of @entity1737 was unknown. We found no studies for NMG. Reported adverse effects included @entity591 , @entity25 , nervousness, and withdrawal symptoms. AUTHORS' CONCLUSIONS: There was no evidence available from RCTs or quasi-RCTs, but some observations from non-randomised studies are available. There is a need for more evidence from suitable forms of prospective RCTs, such as series of n-of-one RCTs, that use appropriate and validated outcome measures.

XXXX for @entity1737 , @entity27939 and the @entity8491 .

@entity1 :: ('9606', 'Species') :: ['participants', 'children', 'people'] @entity4094 :: ('MESH:D009468', 'Disease') :: ['Neuromuscular Disease'] @entity27939 :: ('MESH:D020941', 'Disease') :: ['neonatal myasthenia'] @entity6358 :: ('MESH:D004809', 'Chemical') :: ['ephedrine'] @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia', 'Myasthenia'] @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia'] @entity3161 :: ('MESH:D020511', 'Disease') :: ['neuromuscular junction'] @entity8491 :: ('MESH:D020294', 'Disease') :: ['congenital myasthenic syndromes'] @entity6107 :: ('MESH:D020720', 'Disease') :: ['autoimmune myasthenia gravis'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune MG'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbances']
@entity6358 :: (MESH:D004809,Chemical) :: ['Ephedrine']
